The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RELATIVITY-123: A phase 3, randomized, open-label study of nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) versus regorafenib or trifluridine + tipiracil (TAS-102) in later-line metastatic colorectal cancer (mCRC).
 
Kynan Feeney
No Relationships to Disclose
 
Warren Lance Joubert
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation
 
Rodolfo Eduardo Bordoni
Consulting or Advisory Role - AstraZeneca; Guardant Health; Phillips Gilmore Oncology
Speakers' Bureau - AstraZeneca; Guardant Health; NeoGenomics Laboratories; OncLive Clinical Congress Consultants
 
Sunil Babu
Employment - Fort Wayne Medical Oncology & Hematology
Stock and Other Ownership Interests - Fort Wayne Medical Oncology & Hematology; Lutheran hospital (I)
Honoraria - Amgen; AstraZeneca; Beigene; Bristol-Myers Squibb; Castle Biosciences; Kite, a Gilead company; pharmacosmos
Consulting or Advisory Role - Amgen; argenx; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Kite, a Gilead company
Research Funding - Abbvie (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); argenx (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Novartis (Inst); Sanofi (Inst); Syndax (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Sathiya Marimuthu
Employment - Bristol-Myers Squibb; Hutchison MediPharma (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb; Hutchison MediPharma (I)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Bill Hipkin
Employment - BMS Brazil (I); Merck (I)
Stock and Other Ownership Interests - Bristol Myers Squibb Foundation; Merck
 
Liping Huang
Employment - Bristol Myers Squibb Foundation
Stock and Other Ownership Interests - Bristol Myers Squibb Foundation
 
Rachel Tam
Employment - Bristol Myers Squibb Foundation
Stock and Other Ownership Interests - Bristol Myers Squibb Foundation
 
Mirelis Acosta Rivera
No Relationships to Disclose